OHSU Knight Cancer Institute: Leukemia, Myeloid, Acute trials
The registry lists 11 Leukemia, Myeloid, Acute studies with OHSU Knight Cancer Institute as lead sponsor. 5 are open to participants now and 2 have results posted.
Phase 1 6Phase 2 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell TransplantationRecruitingNCT07548983Phase 1
- Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaRecruitingNCT07228273Phase 2
- Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLRecruitingNCT06504459Phase 2
- Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT06357182Phase 1
- Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT04659616Phase 1
- JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT03557970Phase 2Results posted
- Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
- Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaActive, not recruitingNCT05396859Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedNCT02779283Phase 1
- MRI Assessment of Leukemia Response to TherapyCompletedNCT01537159